Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial
Urologic Oncology: Seminars and Original Investigations | May 31, 2018
Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival
Urologic Oncology: Seminars and Original Investigations | May 27, 2018
Most read this week